Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

81 Press Releases
DateTitleCompany
20 Jul 17 FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication CSL Behring,
Published by
PharmiWeb.com
12 Jul 17 New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B CSL Behring,
Published by
PR Newswire
10 Jul 17 New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A CSL Behring,
Published by
PR Newswire
06 Jul 17 New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017 CSL Behring,
Published by
PR Newswire
26 Jun 17 FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema CSL Behring ,
Published by
PharmiWeb.com
22 May 17 New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award CSL Behring,
Published by
PharmiWeb.com
10 Apr 17 Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World CSL Behring,
Published by
PR Newswire
30 Mar 17 CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients CSL Behring ,
Published by
PharmiWeb.com
29 Mar 17 /DISREGARD RELEASE: CSL Behring/ CSL Behring,
Published by
PR Newswire
29 Mar 17 Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies CSL Behring,
Published by
PR Newswire
30 Aug 16 FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks CSL Behring,
Published by
PharmiWeb.com
29 Jul 16 CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress CSL Behring ,
Published by
PharmiWeb.com
27 Jul 16 CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
26 Jul 16 CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
22 Jul 16 CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation CSL Plasma ,
Published by
PharmiWeb.com
21 Jul 16 CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress CSL Behring ,
Published by
PharmiWeb.com
19 Jul 16 CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
18 Jul 16 U.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE) CSL Behring,
Published by
PR Newswire
19 Apr 16 CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia CSL Behring ,
Published by
PharmiWeb.com
09 Mar 16 CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives CSL Behring,
Published by
PR Newswire
25 Feb 16 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia CSL Behring,
Published by
PharmiWeb.com
22 Dec 15 CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
21 Dec 15 CSL CEO Says Corporate Responsibility And Sustainability Are All About Continuous Improvement CSL Limited,
Published by
PharmiWeb.com
28 Apr 16 CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions CSL Behring ,
Published by
PharmiWeb.com
21 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring,
Published by
PR Newswire
22 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring ,
Published by
PharmiWeb.com
29 Jun 16 CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A CSL Behring ,
Published by
PharmiWeb.com
29 Jun 16 CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 CSL Behring ,
Published by
PharmiWeb.com
19 Mar 16 CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies CSL Behring ,
Published by
PharmiWeb.com
04 Feb 16 CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S. CSL Behring ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.